What is the Origin of GHK-Cu Therapy?

The peptide GHK was first identified in human plasma in 1973 by Dr. Loren Pickart and has since been extensively studied for its roles in tissue remodeling and wound healing. The 'Therapy' designation refers to the clinical use of the synthetic peptide-copper complex to restore youthful levels and stimulate regenerative processes. Its function as a biological signal makes it relevant to advanced longevity protocols.

What is the Mechanism of GHK-Cu Therapy?

The GHK-Cu complex acts by modulating the expression of numerous genes involved in repair and regeneration, including those related to collagen and elastin synthesis, angiogenesis, and nerve outgrowth. Copper is a necessary cofactor for many enzymatic reactions, and the GHK peptide delivers this essential trace element to cells, promoting antioxidant defense and anti-inflammatory signaling. Its multifaceted mechanism supports dermal structural integrity and systemic tissue maintenance.

GHK-Cu Therapy ∞ Area

GHK-Cu Therapy

Meaning

GHK-Cu Therapy is a clinical application involving the administration of the naturally occurring copper-binding tripeptide, Glycyl-L-Histidyl-L-Lysine (GHK), complexed with copper (Cu). This peptide is utilized for its potent regenerative, anti-inflammatory, and antioxidant properties across various tissues, including the skin, hair follicles, and wound beds. Its therapeutic use is centered on leveraging its role as a key signaling molecule that declines with age.